WeedMD Completes Strategic Investment in Blockstrain Technology Corp.

TORONTO, March 19, 2018 (GLOBE NEWSWIRE) — WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a Licensed Producer under Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”), is pleased to announce that it has made a strategic investment in Scorpion Resources Inc., to be renamedBlockstrain Technology Corp. (TSX-V:SR.H) (“Blockstrain”). WeedMD will be amongst the first federally-licensed producers to initiate the integration of blockchain technology into its ecosystem. Blockstrain delivers a secure and immutable blockchain platform to establish global certainty for cannabis strains and their ownership. Blockstrain has developed a comprehensive cannabis genetics archiving platform. The platform aims to transform the way global cannabis business transactions and operations are conducted by providing an incorruptible environment that automates, accelerates and encodes transactions while ensuring privacy and security for all involved parties. “WeedMD has amongst the most robust and expansive library of genetics in the industry. After conducting an extensive review of the blockchain technologies being proposed for and utilized in the cannabis sector, we believe that Blockstrain is best positioned to protect our intellectual property by further validating and securing our best-in-class genetics,” said Derek Pedro, Design, Cultivation and Production Partner at WeedMD. “Our strategic partnership with Blockstrain will position and benefit WeedMD as we obtain and develop new strains to expand our wholesale genetics business and for the benefit of our medical patients.” “We are thrilled to...

Read More

Emblem Selects No Fixed Address as its Agency of Record

TORONTO, March 19, 2018 (GLOBE NEWSWIRE) — Emblem Corp. (TSXV:EMC) (TSXV:EMC.WT) (“Emblem” or the “Corporation”) is pleased to announce that it has selected No Fixed Address (“NFA”) as its agency of record, following a Request for Proposal process that included five agencies. Through the partnership, NFA and Emblem will work together on marketing communication needs and brand initiatives ahead of legalization, with in-market activities set to begin in early Q2. Further details on the selection were published in Strategy Online: About Emblem Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol “EMC” on the TSX Venture Exchange. About No Fixed Address NFA is a full-service creative and digital agency designed to provide clients with the experience of a roster of proven talent and an entrepreneurial underpinning to it all. We approach every client challenge with an open mind allowing us to provide a tailored solution that puts your business first. We have no fixed agenda other than to share our true passion for the business that we’re in and to make our clients...

Read More

Cannabis Giants Join Forces in Cross Border Venture

TORONTO, March 19, 2018 /PRNewswire/ – Cronos Group Inc. (Nasdaq: CRON) (TSX-V: CRON) (“Cronos” or the “Company”) – With Canada on track to legalize adult use of cannabis, two of the world’s largest cannabis companies announced a first-of-its-kind cross border joint venture today that could bring America’s most recognized cannabis brand to Canadian consumers by year’s end. MM Enterprises USA, LLC (“MedMen Enterprises”), a leading U.S. cannabis company with facilities in California, Nevada, and New York, entered into an agreement with Cronos Group, a Canadian licensed producer and distributor of medical cannabis. Cronos, which also has a footprint in Germany, Israel, and Australia, recently became the first pure-play cannabis company traded on a major U.S. stock exchange, the Nasdaq. The joint venture, called MedMen Canada Inc. (“MedMen Canada”), will develop branded products and open stores across Canada, leveraging Cronos’ Canadian reach and expertise, as well as MedMen’s class-defining retail expertise. MedMen is the largest cannabis retail chain in California, which welcomed adult use sales this year. The company owns and operates factories and stores in three states and anticipates going public in Canada in the second quarter of this year. Cronos operates two wholly-owned Canadian Licensed Producers under Health Canada’s Access to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc. and Original BC Ltd. “MedMen Canada will give us entry into an important emerging market for adult use...

Read More

Canopy Growth completes genetics transfer to Spain and provides update on Spanish operations and partnership

SMITHS FALLS, ON and MADRID, March 19, 2018 /CNW/ – Canopy Growth Corporation (TSX: WEED) (“Canopy Growth” or “the Company”) is pleased to confirm that it has successfully completed a transfer of 1,500 cannabis clones to its Madrid-based partner, Alcaliber SA (“Alcaliber”), completing the first phase of a partnership entered into by both parties (the “Parties”) as announced on September 11, 2017. Canopy Growth and Alcaliber enjoy a very strong and committed partnership which will continue to see Alcaliber producing cannabis genetics supplied by Canopy Growth subsidiaries for commercialization purposes. Canopy Growth also wishes to clarify that, contrary to certain speculation, the Company is not in negotiations to acquire Alcaliber. “Our view of the European continent mirrors our Canadian expansion strategy,” said Bruce Linton, Chairman and CEO, Canopy Growth. “We’re diversifying our production capabilities on the continent in anticipation of rapid European market expansion. In addition to a large licenced production footprint in Odense, Denmark we are working closely with our partner Alcaliber to capture market share by scaling supply.” The successful transfer marks the third continent with Canopy Growth genetics growing in soil today. Here’s to Future Growth (not just export) in Europe and beyond. About Canopy Growth Corporation Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation...

Read More

CanniMed Therapeutics Inc. Announces First Quarter Results

SASKATOON, Saskatchewan CanniMed Therapeutics Inc. (TSX:CMED) (“CanniMed” or the “Company”) today released its unaudited financial results of operations for the three months ended January 31, 2018. The information in this news release should be read in conjunction with the Company’s condensed consolidated interim financial statements and notes thereto (unaudited) for the three months ended January 31, 2018 and the Company’s audited consolidated financial statements and notes thereto for the year ended October 31, 2017, available on “CanniMed’s continued success reflects our accomplished team that always strives for excellence and remains focused on high-quality products from GMP compliant production practices,” said Brent Zettl, CEO, CanniMed. “This past quarter we have met many key milestones, including new product introduction and capacity growth. Now, as CanniMed transitions and integrates with Aurora Cannabis, I am confident that our tremendous people will continue to serve our customers well and help Aurora to realize even greater accomplishments.” A summary of key financial and operating results for the first quarter of 2018 is as follows: Highlights • Sales of $4.8 million for the first quarter of 2018 were 41% higher than Q1 2017. • Concentrated cannabis oils sales revenues were approximately 58% of total revenues for the period. • Higher sales revenues were driven by rising demand, as dried equivalent medical cannabis sales in the three months ended January 31, 2018 increased 33% from the...

Read More

Choom™ and ABcann Announce Strategic Investment and Supply Agreement

VANCOUVER and NAPANEE, ON, March 19, 2018 /CNW/ – Choom (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom”) and ABcann Global Corporation (“ABcann”) (TSXV: ABCN, OTCQB: ABCCF) are pleased to announce that the Company has completed a financing of subscription receipts (each, a “Subscription Receipt”) for gross proceeds of $7.0 million including a $4.0 million lead order from ABcann. Strategic Subscription Receipt Financing – $7.0 million Further to Choom’s news release of March 19, 2018, the Company announces that it has completed a strategic private placement of Subscription Receipts concurrent with the execution of a definitive agreement relating to the acquisition of International Tungsten Inc. (“ITI”). In total 11,666,991 Subscription Receipts were issued for gross proceeds of $7.0 million(the “Offering”), including a strategic $4.0 million lead order from ABcann. “ABcann remains committed to becoming a global leader in the cannabis sector. With our strategic investment in Choom, we are signaling a strong move into the recreational market with one of the premium recreation brands in Canada,” stated Barry Fishman, CEO of ABcann. “With our strong cash position of approximately $135,000,000, ABcann intends to pursue other accretive opportunities to diversify our industry presence. We look forward to working with and assisting the Choom team with the supply of our premium grown products.” Supply Agreement Additionally, Choom has entered into a binding agreement (the “Supply Agreement”) with ABcann whereby ABcann, one...

Read More
  • 1
  • 2